PRINTsIPY PASSIVNOY IMMUNIZATsII PALIVIZUMABOM DETEY GRUPPY RISKA TYaZhELOGO TEChENIYa RSV-INFEKTsII


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This article presents the principles of seasonal immunoprophylaxis of severe respiratory syncytial virus infection in at-risk infants, including premature babies born before 35 weeks of gestation, and children with bronchopulmonary dysplasia and hemodynamically significant congenital heart disease up to 2 years of life. Global experience and own author’s data on clinical and instrumental evaluation of the effectiveness and safety of the drug palivizumab are represented.

Full Text

Restricted Access

References

  1. Garenne M, Ronsmans C, Campbell H. The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. World Health Stat Q 1992;45(2-3):180-91.
  2. Everard M. Diagnosis, admission, discharge. Paediatr Respir Rev 2009;10(1):18-20.
  3. Colin A.M, McEnvoy C, Castile R. Respiratory morbidity and lung function in preterm infants 32-36 weeks gestational age. Pediatrics 2010;8(1):1381.
  4. Boyce T.G, Mellen B.G, Mitchel E.F, et all. Rates of hospitalization for respiratory syncytial virus among children in Medicaid. J Pediatr 2000;137:865-70.
  5. Horn S.D, Smout R.J. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003;43:133-41.
  6. Navas G, et al. Improved outcome of RSV infection in a high-risk hospitalized population of Canadian children. J Pediatr 1992;121:348-54.
  7. Давыдова И.В., Яцык Г.В., Тресорукова О.В. и др. Клинико-функциональные особенности течения бронхолегочной дисплазии в первом полугодии жизни // Российский педиатрический журнал 2008. № 6. С. 10-3.
  8. Meissner H.C. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J 2003;22:40-5.
  9. Fauroux B. Special populations. Paediatr Respir Rev 2009;10(1):21-2.
  10. Glezen W.P, Taber L.H, Frank A.L, et al. Rick of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140(6):543-46.
  11. Tatochenko V, Uchaikin V, Gorelove A, et al. Epidemiology of respiratory syncytial virus in children № 2years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study. Clinical Epidemiolgy 2010;2:221-27.
  12. Figueras-Aloy J, Carbonell-Estrany X, Quero J. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004;23(9):815-20.
  13. Rossi G.A, Medici M.C, Arcangeletti M.C, et al. Rick factors for severe RSV-induced low respiratory tract infection over four consecutive epidemics. Eur J Pediatr 2007;166:1267-72.
  14. Law B.J, Langley J.M, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23(9):806-14.
  15. Prince G.A, Jenson A.B, Hemming V.G, et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by intramuscular inoculation of formalin-inactivated virus. Journal of Virology 1986;57:721-28.
  16. Синагис (инструкция по применению). Эбботт Лэбораториз С.А.
  17. Impact-RSV Study Group. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization from Respiratory Syncytial Virus Infection in High-risk Infants. Pediatrics 1998;102:531-37.
  18. Feltes T.F, Cabalka A.K, Meissner H.C, et al. Palivizumab prophilaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamiccaly significant congenital heart disease. J Pediatr 2003;143:532-40.
  19. Henderson J, Hilliard T.N, Sherriff A, at al. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: A longitudinal birth cohort study. Pediatr Allergy Immunol 2005;16:386-92.
  20. Checchia P.A, Nalysnyk L, Fernandes A.W, et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receving prophylaxis with palivizumab: A systematic literature review and meta-analysis. Pediatr Crit Care Med 2011;12(5):580-89.
  21. Turti T.V, Baibarina E.N, Degtiareva E.A, et al. Safety and Efficacy of Palivizumab Prophylaxis in Infants at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation. Europaediatrics 2011;219:138.
  22. Намазова-Баранова Л.С., Турти Т.В., Давыдова И.В. и др. Флоуметрия спокойного дыхания у детей первого года жизни (методические рекомендации). М., 2012. 32 с.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2013 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies